Business Context and Reporting Period
This Form 8-K was filed by Theravance Biopharma, Inc. on March 30, 2026, reporting events occurring on March 27, 2026. The filing addresses a legal settlement regarding the company's product YUPELRI (revefenacin) inhalation solution.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal settlement event rather than periodic financial performance.
Material Changes
The primary material change is the resolution of patent litigation under the Hatch-Waxman Act. Theravance Biopharma, Inc. (along with Mylan) entered into a Settlement Agreement with Mankind Pharma Ltd. and Lifestar Pharma LLC regarding Mankind's Abbreviated New Drug Application (ANDA) for a generic version of YUPELRI.
Guidance, Outlook, and Management Commentary
- Settlement Terms: Theravance and Mylan granted Mankind a royalty-free, non-exclusive license to manufacture and market the generic version of YUPELRI in the United States.
- Launch Date: The licensed launch date for the generic product is set for April 23, 2039.
- Regulatory Review: The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission as required by law.
- Legal Status: All pending Hatch-Waxman litigation relating to YUPELRI has been resolved with this agreement.
Investor Verification Checklist
- Confirm the final approval status of the settlement by the U.S. Department of Justice and the Federal Trade Commission.
- Verify the specific patents covered (U.S. Patent Nos. 11,484,531, 12,048,692, and 12,285,417) and their expiration dates relative to the 2039 launch date.
- Assess the potential impact of the 2039 generic launch date on long-term revenue projections for YUPELRI.
- Review any customary exceptions or provisions in the agreement that might alter the royalty-free status or exclusivity terms.